Literature DB >> 27273122

Applications of the CRISPR/Cas9 system in murine cancer modeling.

Marc Zuckermann, Daisuke Kawauchi, Jan Gronych.   

Abstract

Advanced biological technologies allowing for genetic manipulation of the genome are increasingly being used to unravel the molecular pathogenesis of human diseases. The clustered regulatory interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas) technology started a revolution of this field owing to its flexibility and relative ease of use. Recently, application of the CRISPR/Cas9 system has been extended to in vivo approaches, leveraging its potential for human disease modeling. Particularly in oncological research, where genetic defects in somatic cells are tightly linked to etiology and pathological phenotypes, the CRISPR/Cas technology is being used to recapitulate various types of genetic aberrations. Here we review murine cancer models that have been developed via combining the CRISPR/Cas9 technology with in vivo somatic gene transfer approaches. Exploiting these methodological advances will further accelerate detailed investigations of tumor etiology and treatment.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CRISPR; Cas9; cancer modeling; off-target; somatic mutation

Mesh:

Year:  2016        PMID: 27273122     DOI: 10.1093/bfgp/elw021

Source DB:  PubMed          Journal:  Brief Funct Genomics        ISSN: 2041-2649            Impact factor:   4.241


  4 in total

1.  Expression of PTEN-long mediated by CRISPR/Cas9 can repress U87 cell proliferation.

Authors:  Na Fang; Tingxuan Gu; Yahui Wang; Shuzhen Wang; Fengling Wang; Yang An; Wenqiang Wei; Weijuan Zhang; Xiangqian Guo; Adil J Nazarali; Shaoping Ji
Journal:  J Cell Mol Med       Date:  2017-06-19       Impact factor: 5.310

2.  CRISPR/Cas9 Knockout of Bak Mediates Bax Translocation to Mitochondria in response to TNFα/CHX-induced Apoptosis.

Authors:  Jingtian Zhang; Han Niu; Zhizhuang Joe Zhao; Xueqi Fu; Yuxiang Wang; Xu Zhang; Fuqiang Zhang; Linlin Zeng
Journal:  Biomed Res Int       Date:  2019-09-17       Impact factor: 3.411

Review 3.  New insights on CRISPR/Cas9-based therapy for breast Cancer.

Authors:  Hussein Sabit; Shaimaa Abdel-Ghany; Huseyin Tombuloglu; Emre Cevik; Amany Alqosaibi; Fatma Almulhim; Afnan Al-Muhanaa
Journal:  Genes Environ       Date:  2021-04-29

Review 4.  CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries.

Authors:  K Sreedurgalakshmi; R Srikar; Reena Rajkumari
Journal:  Cancer Gene Ther       Date:  2020-11-15       Impact factor: 5.987

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.